Leukemia Therapeutics Market By Type (Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Others), By Drug Class (Chemotherapy, Targeted Therapy and Immunotherapy), By Distribution channel (Hospital Pharmacies, Drug Store and Retail Pharmacies, Online Providers): Global Opportunity Analysis and Industry Forecast, 2021-2031

Leukemia Therapeutics Market

Leukemia therapeutics are treatments that are used to treat leukemia, a type of cancer that affects the blood and bone marrow. There are several types of leukemia, including acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia (CML). The treatments used for leukemia include chemotherapy, targeted therapy, and immunotherapy. Leukemia therapeutics kill or remove the cancer cells and prevent them from spreading or recurring, while minimizing the damage to healthy cells and tissues.

Key factors driving the growth of the Leukemia therapeutics market include increase in people affected with leukemia, rise in awareness of diagnosis and treatment options for leukemia and high adoption of the key strategies by key players. For instance, in October 2020, AbbVie announced the U.S. Food and Drug Administration (FDA) has provided full approval to VENCLEXTA (venetoclax) in combination with azacitidine, or decitabine, or low-dose cytarabine (LDAC) for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults for 75 years or older people. Patients are becoming more aware of the available treatment options for leukemia, and are more likely to seek treatment, which has increased the demand for leukemia therapeutics. There is an increasing awareness among the general public about cancer and the available treatment options, which has led to more people seeking treatment for leukemia and drive the market growth.

In addition, availability of favorable government policies to improve the access to healthcare and encourage the R&D activities in oncology field boost the market growth. Moreover, development of more effective immunotoxins, alkylating drugs, monoclonal antibodies and multidrug resistant modulators has increased the adoption of leukemia therapeutics. These therapeutics provide the long-lasting effects and improved efficacy in leukemia cell identification. Such advantages provided by the leukemia therapeutics propels the market growth in this region. Furthermore, rise in healthcare expenditure for the treatment of leukemia, which has boosted the growth of the market.

The market also offers growth opportunities to the key players in the market. Large number of companies involved in R&D and new product launches for leukemia are expected to drive the market growth. For instance, according to the data published by ClinicalTrials.gov, a randomized study was conducted to assess the efficacy and safety of Ublituximab in combination with TGR-1202 for patients of chronic lymphocytic leukemia (CLL). Leukemia pipeline products provide advanced efficacy and better patient outcomes than existing treatment. This is attributed to the introduction of new drug classes, monoclonal antibodies, for leukemia. In addition, there are number of R&D activities conducted to develop different types of treatment by using combination of drugs to improve the patients' outcomes for leukemia. Thus, presence of drugs in pipeline is expected to provide lucrative opportunities for the growth of the market.

The leukemia therapeutics market is segmented into type, drug class, distribution channel, and region. On the basis of type, the market is categorized into acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, and others. On the basis of drug class, it is categorized into chemotherapy and targeted therapy & immunotherapy. By distribution channel, it is further divided into hospital pharmacies, drug stores & retail pharmacies and online providers. Region wise, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

The key players profiled in the study include AbbVie Inc. Amgen Inc., Bristol-Myers Squibb Company, Gilead Sciences, Inc., Lupin, Novartis AG, Pfizer Inc., Sanofi, Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Limited. The players in the market have been actively engaged in the adoption key strategy such as product approval to remain competitive and gain advantage over the competitors in the market. For instance, in October 2020, AbbVie Inc. announced the U.S. Food and Drug Administration (FDA) has provided full approval for VENCLEXTA (venetoclax) in combination with azacitidine, decitabine, or low dose cytarabine (LDAC) for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults.

Key Market Insights (Updated)

By type, the chronic lymphocytic leukemia segment was the highest revenue contributor to the market and is estimated to reach $5,778.23 million by 2031, with a highest CAGR.

By drug class, the targeted therapy and immunotherapy segment dominated the global market in 2021.

Based on distribution channel, the hospital pharmacies segment was the highest revenue contributor to the market with a CAGR of 5.9% during the forecast period. However, online providers segment is expected to grow at the highest CAGR during the forecast period.

Based on region, North America garnered the largest revenue share in 2021, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period

Overview

The global leukemia therapeutics market valued for $7,818.63 million in 2021 and is estimated to reach $14,162.48 million by 2031, exhibiting a CAGR of 6.1% from 2022 to 2031.  

Leukemia is a type of blood cancer that affects the blood and bone marrow. It is characterized by the uncontrolled production of abnormal white blood cells, which can interfere with the normal functioning of the blood and the immune system. There are several types of leukemia, including acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia (CML). The rare types of leukemia include chronic myelomonocytic leukemia (CMML), and juvenile myelomonocytic leukemia (JMML). Treatment for these rare forms of leukemia may involve a combination of chemotherapy, and others treatment depending on the type and stage of the leukemia and the overall health of the patient. Symptoms of leukemia can include fatigue, weakness, frequent infections, and easy bruising or bleeding.

A number of commercially available drugs have been developed to treat leukemia and are driving the demand for leukemia therapeutics. Some of the most commonly used drugs include Gleevec, Bosulif, Sprycel, Iculsig, and others. These drugs have shown significant efficacy in the treatment of leukemia and have become the standard of care for many patients. In addition, the development of new and improved drugs for the treatment of leukemia drives the demand for leukemia therapeutics.

The leukemia therapeutics market is experiencing growth owing to rise in cases of leukemia and the number of bone marrow biopsies across the world. In addition, the increase in investment in the R&D activities for leukemia and rise in awareness of the targeted therapies among the population further drive the growth of the leukemia therapeutics market. The introduction of new drugs has led to improved survival rates for patients with leukemia, giving them a better chance of beating the disease which further supports the market growth.

In contrast, the stringent regulatory approvals for the leukemia therapeutics and the side effect of the drugs used in the leukemia treatment impedes the growth of the market. For instance, Onureg (azacitidine) causes dizziness, nausea, vomiting, fatigue, anemia, and low platelet count in patients with leukemia. In addition, patent expiry of the drugs used in the treatment of leukemia and the higher costs involved in the therapies limit the growth of the global leukemia therapeutics market. Moreover, the rise in number of clinical trials for leukemia and new product approvals are anticipated to create newer opportunities in the emerging as well as the developed markets. For instance, in December 2020, Amgen announced the U.S. Food and Drug Administration (FDA) has approved RIABNI (rituximab-arrx), a biosimilar to Rituxan (rituximab), for the treatment of adult patients with chronic lymphocytic leukemia (CLL).

The global leukemia therapeutics market is segmented into type, drug class, distribution channel, and region. By type, the market is categorized into acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, and others. On the basis of drug class, the market is segregated into chemotherapy, and targeted & immunotherapy. By distribution channel, the market is classified into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).  

Major key players that operate in the global leukemia therapeutics market are AbbVie Inc. Amgen Inc., Bristol-Myers Squibb Company, Gilead Sciences, Inc., Lupin, Novartis AG, Pfizer Inc., Sanofi, Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Limited. 

Key Benefits For Stakeholders

●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global leukemia therapeutics market analysis from 2021 to 2031 to identify the prevailing global leukemia therapeutics market opportunities.

●The market research is offered along with information related to key drivers, restraints, and opportunities.

●Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

●In-depth analysis of the global leukemia therapeutics market segmentation assists to determine the prevailing market opportunities.

●Major countries in each region are mapped according to their revenue contribution to the global market.

●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

●The report includes the analysis of the regional as well as global leukemia therapeutics market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

○ Novartis A

Scope of Leukemia Therapeutics Market Report

1.1. Report description

1.2. Key market segments

1.3. Key benefits to the stakeholders

1.4. Research Methodology

1.4.1. Primary research

1.4.2. Secondary research

1.4.3. Analyst tools and models

2.1. CXO Perspective

3.1. Market definition and scope

3.2. Key findings

3.2.1. Top impacting factors

3.2.2. Top investment pockets

3.3. Porter’s five forces analysis

3.3.1. Bargaining power of suppliers

3.3.2. Bargaining power of buyers

3.3.3. Threat of substitutes

3.3.4. Threat of new entrants

3.3.5. Intensity of rivalry

3.4. Market dynamics

3.4.1. Drivers

3.4.1.1. Rise in incidences of leukemia

3.4.1.2. Rise in product approval

3.4.2. Restraints

3.4.2.1. Side-effects and adverse reactions of leukemia therapeutics

3.4.2.2. High cost of leukemia therapeutics

3.4.3. Opportunities

3.4.3.1. High growth potential in developing economies

3.4.3.2. Increase in R&D activities

3.5. COVID-19 Impact Analysis on the market

4.1. Overview

4.1.1. Market size and forecast

4.2. Acute Lymphocytic Leukemia

4.2.1. Key market trends, growth factors and opportunities

4.2.2. Market size and forecast, by region

4.2.3. Market share analysis by country

4.3. Acute Myeloid Leukemia

4.3.1. Key market trends, growth factors and opportunities

4.3.2. Market size and forecast, by region

4.3.3. Market share analysis by country

4.4. Chronic Lymphocytic Leukemia

4.4.1. Key market trends, growth factors and opportunities

4.4.2. Market size and forecast, by region

4.4.3. Market share analysis by country

4.5. Chronic Myeloid Leukemia

4.5.1. Key market trends, growth factors and opportunities

4.5.2. Market size and forecast, by region

4.5.3. Market share analysis by country

4.6. Others

4.6.1. Key market trends, growth factors and opportunities

4.6.2. Market size and forecast, by region

4.6.3. Market share analysis by country

5.1. Overview

5.1.1. Market size and forecast

5.2. Chemotherapy

5.2.1. Key market trends, growth factors and opportunities

5.2.2. Market size and forecast, by region

5.2.3. Market share analysis by country

5.3. Targeted Therapy and Immunotherapy

5.3.1. Key market trends, growth factors and opportunities

5.3.2. Market size and forecast, by region

5.3.3. Market share analysis by country

6.1. Overview

6.1.1. Market size and forecast

6.2. Hospital Pharmacies

6.2.1. Key market trends, growth factors and opportunities

6.2.2. Market size and forecast, by region

6.2.3. Market share analysis by country

6.3. Drug Store and Retail Pharmacies

6.3.1. Key market trends, growth factors and opportunities

6.3.2. Market size and forecast, by region

6.3.3. Market share analysis by country

6.4. Online Providers

6.4.1. Key market trends, growth factors and opportunities

6.4.2. Market size and forecast, by region

6.4.3. Market share analysis by country

7.1. Overview

7.1.1. Market size and forecast By Region

7.2. North America

7.2.1. Key trends and opportunities

7.2.2. Market size and forecast, by Type

7.2.3. Market size and forecast, by Drug Class

7.2.4. Market size and forecast, by Distribution channel

7.2.5. Market size and forecast, by country

7.2.5.1. U.S.

7.2.5.1.1. Key market trends, growth factors and opportunities

7.2.5.1.2. Market size and forecast, by Type

7.2.5.1.3. Market size and forecast, by Drug Class

7.2.5.1.4. Market size and forecast, by Distribution channel

7.2.5.2. Canada

7.2.5.2.1. Key market trends, growth factors and opportunities

7.2.5.2.2. Market size and forecast, by Type

7.2.5.2.3. Market size and forecast, by Drug Class

7.2.5.2.4. Market size and forecast, by Distribution channel

7.2.5.3. Mexico

7.2.5.3.1. Key market trends, growth factors and opportunities

7.2.5.3.2. Market size and forecast, by Type

7.2.5.3.3. Market size and forecast, by Drug Class

7.2.5.3.4. Market size and forecast, by Distribution channel

7.3. Europe

7.3.1. Key trends and opportunities

7.3.2. Market size and forecast, by Type

7.3.3. Market size and forecast, by Drug Class

7.3.4. Market size and forecast, by Distribution channel

7.3.5. Market size and forecast, by country

7.3.5.1. Germany

7.3.5.1.1. Key market trends, growth factors and opportunities

7.3.5.1.2. Market size and forecast, by Type

7.3.5.1.3. Market size and forecast, by Drug Class

7.3.5.1.4. Market size and forecast, by Distribution channel

7.3.5.2. France

7.3.5.2.1. Key market trends, growth factors and opportunities

7.3.5.2.2. Market size and forecast, by Type

7.3.5.2.3. Market size and forecast, by Drug Class

7.3.5.2.4. Market size and forecast, by Distribution channel

7.3.5.3. UK

7.3.5.3.1. Key market trends, growth factors and opportunities

7.3.5.3.2. Market size and forecast, by Type

7.3.5.3.3. Market size and forecast, by Drug Class

7.3.5.3.4. Market size and forecast, by Distribution channel

7.3.5.4. Italy

7.3.5.4.1. Key market trends, growth factors and opportunities

7.3.5.4.2. Market size and forecast, by Type

7.3.5.4.3. Market size and forecast, by Drug Class

7.3.5.4.4. Market size and forecast, by Distribution channel

7.3.5.5. Spain

7.3.5.5.1. Key market trends, growth factors and opportunities

7.3.5.5.2. Market size and forecast, by Type

7.3.5.5.3. Market size and forecast, by Drug Class

7.3.5.5.4. Market size and forecast, by Distribution channel

7.3.5.6. Rest of Europe

7.3.5.6.1. Key market trends, growth factors and opportunities

7.3.5.6.2. Market size and forecast, by Type

7.3.5.6.3. Market size and forecast, by Drug Class

7.3.5.6.4. Market size and forecast, by Distribution channel

7.4. Asia-Pacific

7.4.1. Key trends and opportunities

7.4.2. Market size and forecast, by Type

7.4.3. Market size and forecast, by Drug Class

7.4.4. Market size and forecast, by Distribution channel

7.4.5. Market size and forecast, by country

7.4.5.1. Japan

7.4.5.1.1. Key market trends, growth factors and opportunities

7.4.5.1.2. Market size and forecast, by Type

7.4.5.1.3. Market size and forecast, by Drug Class

7.4.5.1.4. Market size and forecast, by Distribution channel

7.4.5.2. China

7.4.5.2.1. Key market trends, growth factors and opportunities

7.4.5.2.2. Market size and forecast, by Type

7.4.5.2.3. Market size and forecast, by Drug Class

7.4.5.2.4. Market size and forecast, by Distribution channel

7.4.5.3. India

7.4.5.3.1. Key market trends, growth factors and opportunities

7.4.5.3.2. Market size and forecast, by Type

7.4.5.3.3. Market size and forecast, by Drug Class

7.4.5.3.4. Market size and forecast, by Distribution channel

7.4.5.4. Australia

7.4.5.4.1. Key market trends, growth factors and opportunities

7.4.5.4.2. Market size and forecast, by Type

7.4.5.4.3. Market size and forecast, by Drug Class

7.4.5.4.4. Market size and forecast, by Distribution channel

7.4.5.5. South Korea

7.4.5.5.1. Key market trends, growth factors and opportunities

7.4.5.5.2. Market size and forecast, by Type

7.4.5.5.3. Market size and forecast, by Drug Class

7.4.5.5.4. Market size and forecast, by Distribution channel

7.4.5.6. Rest of Asia-Pacific

7.4.5.6.1. Key market trends, growth factors and opportunities

7.4.5.6.2. Market size and forecast, by Type

7.4.5.6.3. Market size and forecast, by Drug Class

7.4.5.6.4. Market size and forecast, by Distribution channel

7.5. LAMEA

7.5.1. Key trends and opportunities

7.5.2. Market size and forecast, by Type

7.5.3. Market size and forecast, by Drug Class

7.5.4. Market size and forecast, by Distribution channel

7.5.5. Market size and forecast, by country

7.5.5.1. Brazil

7.5.5.1.1. Key market trends, growth factors and opportunities

7.5.5.1.2. Market size and forecast, by Type

7.5.5.1.3. Market size and forecast, by Drug Class

7.5.5.1.4. Market size and forecast, by Distribution channel

7.5.5.2. Saudi Arabia

7.5.5.2.1. Key market trends, growth factors and opportunities

7.5.5.2.2. Market size and forecast, by Type

7.5.5.2.3. Market size and forecast, by Drug Class

7.5.5.2.4. Market size and forecast, by Distribution channel

7.5.5.3. South Africa

7.5.5.3.1. Key market trends, growth factors and opportunities

7.5.5.3.2. Market size and forecast, by Type

7.5.5.3.3. Market size and forecast, by Drug Class

7.5.5.3.4. Market size and forecast, by Distribution channel

7.5.5.4. Rest of LAMEA

7.5.5.4.1. Key market trends, growth factors and opportunities

7.5.5.4.2. Market size and forecast, by Type

7.5.5.4.3. Market size and forecast, by Drug Class

7.5.5.4.4. Market size and forecast, by Distribution channel

8.1. Introduction

8.2. Top winning strategies

8.3. Product Mapping of Top 10 Player

8.4. Competitive Dashboard

8.5. Competitive Heatmap

8.6. Top player positioning, 2021

9.1. Abbvie Inc

9.1.1. Company overview

9.1.2. Key Executives

9.1.3. Company snapshot

9.1.4. Operating business segments

9.1.5. Product portfolio

9.1.6. Business performance

9.1.7. Key strategic moves and developments

9.2. Amgen Inc.

9.2.1. Company overview

9.2.2. Key Executives

9.2.3. Company snapshot

9.2.4. Operating business segments

9.2.5. Product portfolio

9.2.6. Business performance

9.2.7. Key strategic moves and developments

9.3. Pfizer Inc.

9.3.1. Company overview

9.3.2. Key Executives

9.3.3. Company snapshot

9.3.4. Operating business segments

9.3.5. Product portfolio

9.3.6. Business performance

9.3.7. Key strategic moves and developments

9.4. Novartis AG

9.4.1. Company overview

9.4.2. Key Executives

9.4.3. Company snapshot

9.4.4. Operating business segments

9.4.5. Product portfolio

9.4.6. Business performance

9.5. Gilead Sciences, Inc.

9.5.1. Company overview

9.5.2. Key Executives

9.5.3. Company snapshot

9.5.4. Operating business segments

9.5.5. Product portfolio

9.5.6. Business performance

9.5.7. Key strategic moves and developments

9.6. Bristol-Myers Squibb Company

9.6.1. Company overview

9.6.2. Key Executives

9.6.3. Company snapshot

9.6.4. Operating business segments

9.6.5. Product portfolio

9.6.6. Business performance

9.6.7. Key strategic moves and developments

9.7. Sanofi

9.7.1. Company overview

9.7.2. Key Executives

9.7.3. Company snapshot

9.7.4. Operating business segments

9.7.5. Product portfolio

9.7.6. Business performance

9.8. Teva Pharmaceutical Industries Limited

9.8.1. Company overview

9.8.2. Key Executives

9.8.3. Company snapshot

9.8.4. Operating business segments

9.8.5. Product portfolio

9.8.6. Business performance

9.9. Lupin

9.9.1. Company overview

9.9.2. Key Executives

9.9.3. Company snapshot

9.9.4. Operating business segments

9.9.5. Product portfolio

9.9.6. Business performance

9.10. Takeda Pharmaceutical Company Limited

9.10.1. Company overview

9.10.2. Key Executives

9.10.3. Company snapshot

9.10.4. Operating business segments

9.10.5. Product portfolio

9.10.6. Business performance

9.10.7. Key strategic moves and development

LIST OF TABLES

TABLE 01. GLOBAL LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 02. LEUKEMIA THERAPEUTICS MARKET FOR ACUTE LYMPHOCYTIC LEUKEMIA, BY REGION, 2021-2031 ($MILLION)

TABLE 03. LEUKEMIA THERAPEUTICS MARKET FOR ACUTE MYELOID LEUKEMIA, BY REGION, 2021-2031 ($MILLION)

TABLE 04. LEUKEMIA THERAPEUTICS MARKET FOR CHRONIC LYMPHOCYTIC LEUKEMIA, BY REGION, 2021-2031 ($MILLION)

TABLE 05. LEUKEMIA THERAPEUTICS MARKET FOR CHRONIC MYELOID LEUKEMIA, BY REGION, 2021-2031 ($MILLION)

TABLE 06. LEUKEMIA THERAPEUTICS MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)

TABLE 07. GLOBAL LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 08. LEUKEMIA THERAPEUTICS MARKET FOR CHEMOTHERAPY, BY REGION, 2021-2031 ($MILLION)

TABLE 09. LEUKEMIA THERAPEUTICS MARKET FOR TARGETED THERAPY AND IMMUNOTHERAPY, BY REGION, 2021-2031 ($MILLION)

TABLE 10. GLOBAL LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 11. LEUKEMIA THERAPEUTICS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)

TABLE 12. LEUKEMIA THERAPEUTICS MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)

TABLE 13. LEUKEMIA THERAPEUTICS MARKET FOR ONLINE PROVIDERS, BY REGION, 2021-2031 ($MILLION)

TABLE 14. LEUKEMIA THERAPEUTICS MARKET, BY REGION, 2021-2031 ($MILLION)

TABLE 15. NORTH AMERICA LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 16. NORTH AMERICA LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 17. NORTH AMERICA LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 18. NORTH AMERICA LEUKEMIA THERAPEUTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 19. U.S. LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 20. U.S. LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 21. U.S. LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 22. CANADA LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 23. CANADA LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 24. CANADA LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 25. MEXICO LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 26. MEXICO LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 27. MEXICO LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 28. EUROPE LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 29. EUROPE LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 30. EUROPE LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 31. EUROPE LEUKEMIA THERAPEUTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 32. GERMANY LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 33. GERMANY LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 34. GERMANY LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 35. FRANCE LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 36. FRANCE LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 37. FRANCE LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 38. UK LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 39. UK LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 40. UK LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 41. ITALY LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 42. ITALY LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 43. ITALY LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 44. SPAIN LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 45. SPAIN LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 46. SPAIN LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 47. REST OF EUROPE LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 48. REST OF EUROPE LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 49. REST OF EUROPE LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 50. ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 51. ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 52. ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 53. ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 54. JAPAN LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 55. JAPAN LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 56. JAPAN LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 57. CHINA LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 58. CHINA LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 59. CHINA LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 60. INDIA LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 61. INDIA LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 62. INDIA LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 63. AUSTRALIA LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 64. AUSTRALIA LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 65. AUSTRALIA LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 66. SOUTH KOREA LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 67. SOUTH KOREA LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 68. SOUTH KOREA LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 69. REST OF ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 70. REST OF ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 71. REST OF ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 72. LAMEA LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 73. LAMEA LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 74. LAMEA LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 75. LAMEA LEUKEMIA THERAPEUTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 76. BRAZIL LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 77. BRAZIL LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 78. BRAZIL LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 79. SAUDI ARABIA LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 80. SAUDI ARABIA LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 81. SAUDI ARABIA LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 82. SOUTH AFRICA LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 83. SOUTH AFRICA LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 84. SOUTH AFRICA LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 85. REST OF LAMEA LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 86. REST OF LAMEA LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 87. REST OF LAMEA LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 88. ABBVIE INC: KEY EXECUTIVES

TABLE 89. ABBVIE INC: COMPANY SNAPSHOT

TABLE 90. ABBVIE INC: PRODUCT SEGMENTS

TABLE 91. ABBVIE INC: PRODUCT PORTFOLIO

TABLE 92. ABBVIE INC: KEY STRATERGIES

TABLE 93. AMGEN INC.: KEY EXECUTIVES

TABLE 94. AMGEN INC.: COMPANY SNAPSHOT

TABLE 95. AMGEN INC.: PRODUCT SEGMENTS

TABLE 96. AMGEN INC.: PRODUCT PORTFOLIO

TABLE 97. AMGEN INC.: KEY STRATERGIES

TABLE 98. PFIZER INC.: KEY EXECUTIVES

TABLE 99. PFIZER INC.: COMPANY SNAPSHOT

TABLE 100. PFIZER INC.: PRODUCT SEGMENTS

TABLE 101. PFIZER INC.: PRODUCT PORTFOLIO

TABLE 102. PFIZER INC.: KEY STRATERGIES

TABLE 103. NOVARTIS AG: KEY EXECUTIVES

TABLE 104. NOVARTIS AG: COMPANY SNAPSHOT

TABLE 105. NOVARTIS AG: PRODUCT SEGMENTS

TABLE 106. NOVARTIS AG: PRODUCT PORTFOLIO

TABLE 107. GILEAD SCIENCES, INC.: KEY EXECUTIVES

TABLE 108. GILEAD SCIENCES, INC.: COMPANY SNAPSHOT

TABLE 109. GILEAD SCIENCES, INC.: PRODUCT SEGMENTS

TABLE 110. GILEAD SCIENCES, INC.: PRODUCT PORTFOLIO

TABLE 111. GILEAD SCIENCES, INC.: KEY STRATERGIES

TABLE 112. BRISTOL-MYERS SQUIBB COMPANY: KEY EXECUTIVES

TABLE 113. BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT

TABLE 114. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT SEGMENTS

TABLE 115. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO

TABLE 116. BRISTOL-MYERS SQUIBB COMPANY: KEY STRATERGIES

TABLE 117. SANOFI: KEY EXECUTIVES

TABLE 118. SANOFI: COMPANY SNAPSHOT

TABLE 119. SANOFI: PRODUCT SEGMENTS

TABLE 120. SANOFI: PRODUCT PORTFOLIO

TABLE 121. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES

TABLE 122. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT

TABLE 123. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT SEGMENTS

TABLE 124. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO

TABLE 125. LUPIN: KEY EXECUTIVES

TABLE 126. LUPIN: COMPANY SNAPSHOT

TABLE 127. LUPIN: PRODUCT SEGMENTS

TABLE 128. LUPIN: PRODUCT PORTFOLIO

TABLE 129. TAKEDA PHARMACEUTICAL COMPANY LIMITED: KEY EXECUTIVES

TABLE 130. TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT

TABLE 131. TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT SEGMENTS

TABLE 132. TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT PORTFOLIO

TABLE 133. TAKEDA PHARMACEUTICAL COMPANY LIMITED: KEY STRATERGIES LIST OF FIGURES

FIGURE 01. LEUKEMIA THERAPEUTICS MARKET, 2021-2031

FIGURE 02. SEGMENTATION OF LEUKEMIA THERAPEUTICS MARKET, 2021-2031

FIGURE 03. TOP INVESTMENT POCKETS IN LEUKEMIA THERAPEUTICS MARKET (2022-2031)

FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIERS

FIGURE 05. MODERATE BARGAINING POWER OF BUYERS

FIGURE 06. MODERATE THREAT OF SUBSTITUTES

FIGURE 07. HIGH THREAT OF NEW ENTRANTS

FIGURE 08. MODERATE INTENSITY OF RIVALRY

FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALLEUKEMIA THERAPEUTICS MARKET

FIGURE 10. LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021(%)

FIGURE 11. COMPARATIVE SHARE ANALYSIS OF LEUKEMIA THERAPEUTICS MARKET FOR ACUTE LYMPHOCYTIC LEUKEMIA, BY COUNTRY 2021-2031(%)

FIGURE 12. COMPARATIVE SHARE ANALYSIS OF LEUKEMIA THERAPEUTICS MARKET FOR ACUTE MYELOID LEUKEMIA, BY COUNTRY 2021-2031(%)

FIGURE 13. COMPARATIVE SHARE ANALYSIS OF LEUKEMIA THERAPEUTICS MARKET FOR CHRONIC LYMPHOCYTIC LEUKEMIA, BY COUNTRY 2021-2031(%)

FIGURE 14. COMPARATIVE SHARE ANALYSIS OF LEUKEMIA THERAPEUTICS MARKET FOR CHRONIC MYELOID LEUKEMIA, BY COUNTRY 2021-2031(%)

FIGURE 15. COMPARATIVE SHARE ANALYSIS OF LEUKEMIA THERAPEUTICS MARKET FOR OTHERS, BY COUNTRY 2021-2031(%)

FIGURE 16. LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021(%)

FIGURE 17. COMPARATIVE SHARE ANALYSIS OF LEUKEMIA THERAPEUTICS MARKET FOR CHEMOTHERAPY, BY COUNTRY 2021-2031(%)

FIGURE 18. COMPARATIVE SHARE ANALYSIS OF LEUKEMIA THERAPEUTICS MARKET FOR TARGETED THERAPY AND IMMUNOTHERAPY, BY COUNTRY 2021-2031(%)

FIGURE 19. LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021(%)

FIGURE 20. COMPARATIVE SHARE ANALYSIS OF LEUKEMIA THERAPEUTICS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2021-2031(%)

FIGURE 21. COMPARATIVE SHARE ANALYSIS OF LEUKEMIA THERAPEUTICS MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY COUNTRY 2021-2031(%)

FIGURE 22. COMPARATIVE SHARE ANALYSIS OF LEUKEMIA THERAPEUTICS MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2021-2031(%)

FIGURE 23. LEUKEMIA THERAPEUTICS MARKET BY REGION, 2021

FIGURE 24. U.S. LEUKEMIA THERAPEUTICS MARKET, 2021-2031 ($MILLION)

FIGURE 25. CANADA LEUKEMIA THERAPEUTICS MARKET, 2021-2031 ($MILLION)

FIGURE 26. MEXICO LEUKEMIA THERAPEUTICS MARKET, 2021-2031 ($MILLION)

FIGURE 27. GERMANY LEUKEMIA THERAPEUTICS MARKET, 2021-2031 ($MILLION)

FIGURE 28. FRANCE LEUKEMIA THERAPEUTICS MARKET, 2021-2031 ($MILLION)

FIGURE 29. UK LEUKEMIA THERAPEUTICS MARKET, 2021-2031 ($MILLION)

FIGURE 30. ITALY LEUKEMIA THERAPEUTICS MARKET, 2021-2031 ($MILLION)

FIGURE 31. SPAIN LEUKEMIA THERAPEUTICS MARKET, 2021-2031 ($MILLION)

FIGURE 32. REST OF EUROPE LEUKEMIA THERAPEUTICS MARKET, 2021-2031 ($MILLION)

FIGURE 33. JAPAN LEUKEMIA THERAPEUTICS MARKET, 2021-2031 ($MILLION)

FIGURE 34. CHINA LEUKEMIA THERAPEUTICS MARKET, 2021-2031 ($MILLION)

FIGURE 35. INDIA LEUKEMIA THERAPEUTICS MARKET, 2021-2031 ($MILLION)

FIGURE 36. AUSTRALIA LEUKEMIA THERAPEUTICS MARKET, 2021-2031 ($MILLION)

FIGURE 37. SOUTH KOREA LEUKEMIA THERAPEUTICS MARKET, 2021-2031 ($MILLION)

FIGURE 38. REST OF ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET, 2021-2031 ($MILLION)

FIGURE 39. BRAZIL LEUKEMIA THERAPEUTICS MARKET, 2021-2031 ($MILLION)

FIGURE 40. SAUDI ARABIA LEUKEMIA THERAPEUTICS MARKET, 2021-2031 ($MILLION)

FIGURE 41. SOUTH AFRICA LEUKEMIA THERAPEUTICS MARKET, 2021-2031 ($MILLION)

FIGURE 42. REST OF LAMEA LEUKEMIA THERAPEUTICS MARKET, 2021-2031 ($MILLION)

FIGURE 43. TOP WINNING STRATEGIES, BY YEAR

FIGURE 44. TOP WINNING STRATEGIES, BY DEVELOPMENT

FIGURE 45. TOP WINNING STRATEGIES, BY COMPANY

FIGURE 46. PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 47. COMPETITIVE DASHBOARD

FIGURE 48. COMPETITIVE HEATMAP: LEUKEMIA THERAPEUTICS MARKET

FIGURE 49. TOP PLAYER POSITIONING, 2021

FIGURE 50. ABBVIE INC: NET REVENUE, 2019-2021 ($MILLION)

FIGURE 51. ABBVIE INC: REVENUE SHARE BY SEGMENT, 2021 (%)

FIGURE 52. ABBVIE INC: REVENUE SHARE BY REGION, 2021 (%)

FIGURE 53. AMGEN INC.: NET REVENUE, 2019-2021 ($MILLION)

FIGURE 54. AMGEN INC.: REVENUE SHARE BY REGION, 2021 (%)

FIGURE 55. PFIZER INC.: NET REVENUE, 2019-2021 ($MILLION)

FIGURE 56. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2021 (%)

FIGURE 57. PFIZER INC.: REVENUE SHARE BY REGION, 2021 (%)

FIGURE 58. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)

FIGURE 59. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 60. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 61. GILEAD SCIENCES, INC.: NET REVENUE, 2019-2021 ($MILLION)

FIGURE 62. BRISTOL-MYERS SQUIBB COMPANY: NET SALES, 2019-2021 ($MILLION)

FIGURE 63. BRISTOL-MYERS SQUIBB COMPANY: REVENUE SHARE BY REGION, 2021 (%)

FIGURE 64. SANOFI: NET SALES, 2020-2022 ($MILLION)

FIGURE 65. SANOFI: REVENUE SHARE BY SEGMENT, 2021 (%)

FIGURE 66. SANOFI: REVENUE SHARE BY REGION, 2021 (%)

FIGURE 67. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: NET REVENUE, 2019-2021 ($MILLION)

FIGURE 68. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: REVENUE SHARE BY SEGMENT, 2021 (%)

FIGURE 69. LUPIN: NET SALES, 2019-2021 ($MILLION)

FIGURE 70. LUPIN: REVENUE SHARE BY REGION, 2021 (%)

FIGURE 71. TAKEDA PHARMACEUTICAL COMPANY LIMITED: NET REVENUE, 2019-2021 ($MILLION)

FIGURE 72. TAKEDA PHARMACEUTICAL COMPANY LIMITED: REVENUE SHARE BY REGION, 2021 (%